Adalimumab treatment of resistant chondrocalcinosis
Makaleler > Tam Makale · 2024
Yazarlar: Fatih Tastekin, Kenan AKSU
REUMATOLOGIA CLINICA, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Scopus, 2024, cilt 20, ss 452-453
DOI: 10.1016/j.reuma.2024.06.003
Özet
In this article, we present a case of resistant chondrocalcinosis who had a good response with 40 mg subcutaneous adalimumab. To our knowledge, this is the first report using adalimumab successfully in severe CPDD. Anti-TNF therapy can be a good therapeutic option for second line therapy in CPPD.